Rats were divided randomly into six groups: control group (n = 10); diltiazem hydrochloride
1 mg/kg body wt.
This drug can reduce toxic and side effects of chemotherapy and has a notable curative effect on cataracts and vitreous opacities in early stages -- Carbazochrome Sodium Sulfonate Injection: for treatment of the urinary system, upper digestive tract, respiratory system and obstetric hemorrhage; -- Diltiazem Hydrochloride
Injection: for treatment of paroxysmal supraventricular tachycardia and unstable angina pectoris.
AMEX: AKN) today announced that it has received an ANDA approval for Diltiazem Hydrochloride
Injection, 5mg/mL in 25 mL vials.
9 /PRNewswire/ -- Andrx Corporation (Nasdaq: ADRX) today announced that the United States Food and Drug Administration (FDA) has accepted its Abbreviated New Drug Application (ANDA) submissions for bioequivalent versions of Tiazac(TM), a once-a-day Diltiazem Hydrochloride
Extended-release Capsule marketed by Biovail Corporation International (NYSE: BVF) and for Naprelan(R), a once-a-day Naproxen Sodium Extended-release Tablet, marketed by Wyeth Laboratories, Inc.
July 10 /PRNewswire/ -- Andrx Corporation (Nasdaq: ADRX) announced that on July 9, 1998 the United States Food and Drug Administration (FDA) granted final marketing approval of its Abbreviated New Drug Application (ANDA) for all four strengths of extended-release diltiazem hydrochloride
capsules bioequivalent to Cardizem(R) CD.
Tiazac(R) XC is a novel, extended-release formulation of diltiazem hydrochloride
that features a new Diffusion Technology (DiTech(TM)) delivery system designed for night-time administration, resulting in improved 24-hour blood-pressure (BP) control with additional BP control during the early morning hours.
has entered a temporary restraining order prohibiting Mylan Pharmaceuticals from "shipping or otherwise distributing" its once-a-day diltiazem hydrochloride
extended-release capsules bioequivalent to Dilacor XR(TM).
TORONTO -- Biovail Corporation (NYSE:BVF)(TSX:BVF) announced today that the company's supplemental New Drug Submission (sNDS) for TIAZAC(R) XC, a once-daily extended-release formulation of diltiazem hydrochloride
, for the treatment of angina, has been accepted for review by the Therapeutic Products Directorate (TPD).
16 /PRNewswire/ -- Andrx Corporation (Nasdaq: ADRX) today announced that the United States Food and Drug Administration (FDA) has granted tentative approval of its Abbreviated New Drug Application (ANDA) for all four strengths of extended-release diltiazem hydrochloride
capsules bioequivalent to Hoechst Marion Roussel's (HMR) Cardizem(R) CD.
strengths of its Diltiazem Hydrochloride
Extended-release Capsules that are bioequivalent to Tiazac(R).
Biovail Corporation (NYSE, TSX: BVF) today announced positive Phase III clinical trial results of the new graded release formulation of diltiazem hydrochloride
(G-99) in chronic stable angina pectoris.
Manufactured by Biovail Corporation and marketed by Forest Laboratories, Tiazac(R) is a once-a-day Diltiazem Hydrochloride
Extended-release Capsule used in the treatment of hypertension and chronic stable angina, with 1999 U.
International pharmaceutical and health care company F H Faulding & Co Limited (Faulding) today announced that its US based oral generic business, Purepac Pharmaceuticals (Purepac), has received US Patent 6,033,687, covering its technology for once-a-day delivery of diltiazem hydrochloride
, the active ingredient in its recently launched generic version of Cardizem(r) CD.